Skip to main content
Publications
Saif MW, Parikh R , Ray D, Kaye JA, Kurosky SK, Thomas K, Ramirez RA, Halfdanarson TR, Beveridge TJR, Mirakhur B, Nagar SP , Soares HP. Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors . J Gastrointest Oncol. 2019 Aug;10(4):674-87. doi: 10.21037/jgo.2019.03.11
Julvez J, Paus T, Bellinger D, Eskenazi B, Tiemeier H, Pearce N, Ritz B, White T, Ramchandani P, Gispert JD, Desrivieres S, Brouwer R, Boucher O, Alemany S, Lopez-Vicente M, Suades-Gonzalez E, Forns J , Grandjean P, Sunyer J. Environment and brain development: challenges in the global context . Neuroepidemiology. 2016;46(2):79-82. doi: 10.1159/000442256
Samelson EJ, Miller PD, Christiansen C, Daizedeh NS, Grazette L, Anthony MS , Egbuna O, Wang A, Siddhanti SR, Cheung AM, Franchimont N, Kiel DP. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk . J Bone Miner Res. 2014 Feb;29(2):450-7. doi: 10.1002/jbmr.2043